#AI reads Urine# Rapid urine screening and staging of chronic kidney disease via NAD(P)H-activated dual-salt fluorescent probe

This study developed a dual-salt fluorescent probe named CKD-pro, which enables non-invasive and rapid screening and staging of chronic kidney disease (CKD) by detecting the level of NAD(P)H in urine. The core mechanism is that NAD(P)H reduces the quinolinium moiety of the probe, transforming its structure into a donor–π–acceptor configuration, which in turn generates a rapid fluorescence response at 585 nm. The probe has a detection limit of 20 nM for NAD(P)H, a response time of less than 2 minutes, and features high selectivity and biocompatibility. In cellular experiments, it was proven capable of real-time monitoring of NAD(P)H dynamics in G6PD-knockout cancer cells and HK-2 renal cells under hypoxic conditions. In clinical validation, urine samples from 30 CKD patients and 10 healthy controls were tested, showing that the fluorescence signal in the urine of patients was significantly higher than that of healthy individuals and was inversely correlated with eGFR. The probe achieved AUC values of 0.847 for distinguishing CKD patients from healthy people and 0.915 for classifying mild-to-moderate (stages 1–3) and severe (stages 4–5) CKD, outperforming traditional urine markers. It thus provides a new tool for the non-invasive diagnosis and disease assessment of CKD.

Talanta. 2026 Jan 31:303:129470. doi: 10.1016/j.talanta.2026.129470.

Youhe Gao

Statement: During the preparation of this work the author(s) used Doubao / AI reading for summarizing the content. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.

For earlier AI Reads Urine articles：

https://www.keaipublishing.com/en/journals/advances-in-biomarker-sciences-and-technology/ai-reads-urine/